CD19 and graft versus host disease: Additionally, Liu et al. reported phase I and II trial outcomes using CD19 CAR-NK cells, revealing a rapid response in patients with CD19+ cancer with relapsed or refractory conditions, without apparent associations between effectors and adverse effects, including neurotoxicity, cytokine release syndrome, or GVHD [66].